Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?
- Clinical Pharmacology of Dronedarone: Implications for the Therapy of Atrial Fibrillation. Dorian, Paul // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2010 Supplement, Vol. 15 Issue 4, p15S
Dronedarone, a recently approved antiarrhythmic agent, is a chemical analog of amiodarone. It has an approximately 15% bioavailability, with plasma concentrations markedly increasing after a high-fat meal; it is recommended to be taken with food. The primary metabolic clearance pathway for...
- Dofetilide: A Review of its Use in Atrial Fibrillation and Atrial Flutter. McClellan, K.J.; Markham, A. // Drugs;Dec1999, Vol. 58 Issue 6, p1043
Dofetilide is a â€˜pureâ€™ class III antiarrhythmic agent which has demonstrated efficacy in the conversion of atrial fibrillation or flutter to sinus rhythm and the maintenance of sinus rhythm. By blocking the rapid component of the cardiac delayed rectifier potassium current (I),...
- Amiodarone for Atrial Fibrillation. Kirchner, Jeffrey T. // American Family Physician;12/15/2000, Vol. 62 Issue 12, p2685
Presents a study by P.E. Vardas and others to evaluate the efficacy and safety of amiodarone in the treatment of atrial fibrillation of long or short duration. Description of the study and its results; Conclusion that amiodarone is a safe and effective method for termination of atrial fibrillation.
- Amiodarone for the Treatment of Atrial Fibrillation. Kirchner, Jeffrey T. // American Family Physician;9/1/2000, Vol. 62 Issue 5, p1155
Presents information on a study by D. Roy and others comparing amiodarone with sotalol and propafenone in the prevention of recurrent atrial fibrillation. Description of the study and its results; Conclusion that amiodarone is significantly more effective than sotalol or propafenone in...
- No difference after ablation found in patients treated with antiarrhythmic drugs. // Cardiology Today;May2011, Vol. 14 Issue 5, p17
This article discusses a clinical trial on atrial fibrillation in patients treated with antiarrhythmic drugs.
- Antiarrhythmic for atrial fibrillation and flutter. // Modern Medicine;Mar96, Vol. 64 Issue 3, p33
Reports on the marketing approval given Ibutilide fumarate, an antiarrhythmic drug for atrial fibrillation or atrial flutter. Duration of potency; Side effects.
- Antiarrhythmic drug therapy in treating AF. McBride, Brian F. // Cardiology Today;Dec2009, Vol. 12 Issue 12, p9
The article discusses the use of antiarrhythmic drug therapy in patients with atrial fibrillation in the U.S.
- Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials. Duray, Gabor Z.; Schmitt, Jörnn; Hohnloser, Stefan H. // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2010 Supplement, Vol. 15 Issue 4, p19S
Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation. The drug was developed for the treatment of atrial fibrillation (AF). The phase II Dronedarone...
- Atrial Fibrillation-The Final Frontier. Govindan, Malini; Savelieva, Irina; Catanchin, Andrei; Camm, A. John // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2010 Supplement, Vol. 15 Issue 4, p36S
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and represents a significant health care issue. The diagnosis and management of AF uses a significant proportion of the health care budget and is responsible for substantial morbidity and mortality. Restoration and...